De Pauw Vincent, Pezzullo Martina, Bali Maria Antonietta, El Moussaoui Imad, Racu Marie-Lucie, D'haene Nicky, Bouchart Christelle, Closset Jean, Van Laethem Jean-Luc, Navez Julie
Medico-Surgical Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Department of Radiology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium.
Acta Chir Belg. 2023 Jun;123(3):257-265. doi: 10.1080/00015458.2021.1979173. Epub 2021 Sep 17.
Concomitant venous resection during pancreaticoduodenectomy (PD) for pancreatic adenocarcinoma with mesenterico-portal vein involvement is increasingly performed to achieve oncological resection. This study aims to report a single centre experience in peritoneal patch (PP) as autologous graft for vascular reconstruction (VR) during PD.
A retrospective analysis of all patients who underwent PD + VR with PP between December 2019 and September 2020 was performed, using a prospective collected database. Postoperative outcome and pathological margins were evaluated. Venous patency was assessed by computed tomography at day 7 and week 12 post surgery.
Fifteen patients underwent PD + VR with PP reconstruction for pancreatic cancer, including one total pancreatectomy. VR consisted of lateral ( = 14) or tubular ( = 1) patch. The median PP length was 30 mm [26.3-33.8] and venous clamping time 30 min [27.5-39.0]. Computed tomography showed a patent VR in 93.3% and 53.3% after 7 days and 12 weeks, respectively; venous patency loss was always asymptomatic. The only postoperative VR-related complication was one mesenteric venous thrombosis. Five other patients experienced VR-unrelated complications: septic shock ( = 3), biliary fistula ( = 1) and post-traumatic subdural hematoma ( = 1). Mortality was nihil. At pathology, R0 resection (≥1 mm) was observed in 40.0% (6/15), venous margin was free in 46.7% (7/15), and venous wall was involved in 40.0% (6/15).
Use of PP as venous substitute during PD + VR is safe and feasible with an acceptable postoperative morbidity, and a decreased but asymptomatic venous patency after 12 weeks which should question the role of anticoagulation therapy.
对于肠系膜门静脉受累的胰腺腺癌患者,在胰十二指肠切除术(PD)期间进行同期静脉切除以实现肿瘤切除的情况越来越普遍。本研究旨在报告单中心使用腹膜补片(PP)作为自体移植物在PD期间进行血管重建(VR)的经验。
使用前瞻性收集的数据库,对2019年12月至2020年9月期间所有接受PD + VR联合PP治疗的患者进行回顾性分析。评估术后结局和病理切缘。术后第7天和第12周通过计算机断层扫描评估静脉通畅情况。
15例患者因胰腺癌接受了PD + VR联合PP重建术,其中1例行全胰切除术。VR包括侧方补片(n = 14)或管状补片(n = 1)。PP的中位长度为30 mm [26.3 - 33.8],静脉阻断时间为30分钟 [27.5 - 39.0]。计算机断层扫描显示,术后7天和12周时VR通畅率分别为93.3%和53.3%;静脉通畅性丧失始终无症状。唯一与术后VR相关的并发症是1例肠系膜静脉血栓形成。另外5例患者出现了与VR无关的并发症:感染性休克(n = 3)、胆瘘(n = 1)和创伤后硬膜下血肿(n = 1)。无死亡病例。病理检查显示,40.0%(6/15)的患者实现了R0切除(≥1 mm),46.7%(7/15)的患者静脉切缘阴性,40.0%(6/15)的患者静脉壁受累。
在PD + VR期间使用PP作为静脉替代物是安全可行的,术后发病率可接受,术后12周静脉通畅率虽有所下降但无症状,这对抗凝治疗的作用提出了质疑。